On the basis of these promising results, and considering the impact of CTLA-4 and EGFR not only on tumor cell signaling pathways but also on the immune system [27], we decided to construct a novel immunoconjugate by chemically linking the Fc region of ipilimumab mAb with the amino-terminated CL4 aptamer, as we previously reported for other immunoconjugates [39]. This evidence concerns the gene CTLA4 and neoplasm.